Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's afte

Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well

Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in

Preliminary data reinforces IMNN-001 immunotherapy's potential for success in the rapidly recruiting

Imunon Inc. (NASDAQ:IMNN) on Tuesday reported new preliminary findings from its ongoing Phase 2 mini

Imunon reports early Phase 2 data showing lower residual disease and higher ctDNA clearance with IMN

Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-mark

On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing

LAWRENCEVILLE, N. J. , June 22, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-sta

Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.7

Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript

IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clin

LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage

Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript

IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningf

The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial ros

LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-sta

Imunon (NASDAQ: IMNN - Get Free Report) will likely be posting its Q4 2025 results before the market

Imunon (NASDAQ: IMNN - Get Free Report) and Pharma Mar (OTCMKTS:PHMMF - Get Free Report) are both me

Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study Khursheed Anwer, Ph.D

Imunon (NASDAQ: IMNN - Get Free Report) and Allogene Therapeutics (NASDAQ: ALLO - Get Free Report) a

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quart

Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $

  During Thursday's session, 406 companies made new 52-week lows.

  On Tuesday, 386 stocks made new 52-week lows.

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterl

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings

  On Wednesday, 220 stocks hit new 52-week lows.

  On Monday, 76 companies set new 52-week lows.

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quart

  During Friday's trading, 293 companies set new 52-week lows.

Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly